Moderna, Inc. (MRNA) Bundle
An Overview of Moderna, Inc. (MRNA)
General Summary of Moderna, Inc. (MRNA)
Moderna, Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, founded in 2010. The company specializes in developing messenger RNA (mRNA) therapeutics and vaccines.
| Company Detail | Specific Information |
|---|---|
| Founding Year | 2010 |
| Headquarters | Cambridge, Massachusetts |
| Primary Focus | mRNA Technology Therapeutics and Vaccines |
Key product areas include:
- COVID-19 Vaccine (Spikevax)
- Respiratory Syncytial Virus (RSV) Vaccine
- Influenza Vaccines
- Rare Disease Therapeutics
- Cancer Immunotherapies
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $6.236 billion |
| Net Income | $2.056 billion |
| COVID-19 Vaccine Sales | $4.36 billion |
Industry Leadership
Moderna ranks among the top biotechnology companies globally in mRNA technology development, with significant market presence in vaccine innovation.
| Market Position | Details |
|---|---|
| Global mRNA Market Share | Approximately 22% |
| Research & Development Investment | $2.4 billion in 2023 |
Mission Statement of Moderna, Inc. (MRNA)
Mission Statement of Moderna, Inc. (MRNA)
Moderna's mission statement focuses on delivering transformative medicines through messenger RNA (mRNA) technology.
Core Components of Mission Statement
Technological Innovation
Moderna's commitment to mRNA platform demonstrated through:
- 17 development candidates across infectious diseases, oncology, cardiovascular, and rare genetic diseases
- $2.9 billion invested in research and development in 2022
- Over 44 clinical programs in development as of 2023
Product Development Metrics
| Category | Number of Programs | Development Stage |
|---|---|---|
| Infectious Diseases | 14 | Clinical |
| Oncology | 12 | Clinical |
| Rare Genetic Diseases | 9 | Preclinical/Clinical |
Financial Performance Indicators
Key financial metrics supporting mission statement:
- Total Revenue: $6.2 billion in 2022
- Research and Development Expenses: $2.9 billion in 2022
- Cash and Investments: $4.7 billion as of December 31, 2022
Technology Platform Capabilities
Moderna's mRNA technology platform capabilities:
- Over 1,000 issued patents globally
- 24 unique mRNA technological platforms
- Scalable manufacturing capacity of 1 billion doses annually
Strategic Focus Areas
| Focus Area | Number of Programs |
|---|---|
| Prophylactic Vaccines | 8 |
| Cancer Vaccines | 6 |
| Rare Disease Treatments | 9 |
Vision Statement of Moderna, Inc. (MRNA)
Vision Statement of Moderna, Inc. (MRNA)
Transformative mRNA Technology PlatformModerna's vision focuses on leveraging mRNA technology to develop transformative medicines across multiple therapeutic areas. As of 2024, the company has developed 49 development candidates and 27 clinical programs.
| Therapeutic Area | Number of Programs |
|---|---|
| Infectious Diseases | 10 |
| Oncology | 8 |
| Rare Diseases | 6 |
| Cardiovascular | 3 |
Moderna aims to address global health challenges through innovative mRNA technologies. In 2023, the company generated $6.7 billion in total revenue, with COVID-19 vaccine sales accounting for $3.4 billion.
- Research and Development Expenditure: $2.1 billion in 2023
- Patent Portfolio: 1,500+ patents worldwide
- Global Manufacturing Capacity: 1 billion vaccine doses annually
The company's vision emphasizes personalized medicine through targeted mRNA therapies. Current pipeline includes treatments for:
- Cancer immunotherapies
- Personalized cancer vaccines
- Rare genetic disorders
| Clinical Stage | Number of Programs |
|---|---|
| Preclinical | 22 |
| Phase 1 | 12 |
| Phase 2 | 9 |
| Phase 3 | 6 |
Moderna's strategic vision centers on maintaining technological leadership in mRNA platforms. Market capitalization as of January 2024: $36.2 billion.
Core Values of Moderna, Inc. (MRNA)
Core Values of Moderna, Inc. (MRNA) in 2024
Innovation and Scientific Excellence
Moderna invested $2.4 billion in R&D expenses in 2023. The company filed 937 patent applications and maintained 671 granted patents as of Q4 2023.
| R&D Metric | 2023 Value |
|---|---|
| R&D Expenses | $2.4 billion |
| Patent Applications | 937 |
| Granted Patents | 671 |
Patient-Centered Approach
Moderna's clinical trials in 2023 involved 56,342 participants across various therapeutic areas.
- Vaccine development programs: 24
- Therapeutic areas covered: 7
- Global clinical trial sites: 38 countries
Ethical Leadership and Transparency
Moderna's 2023 ESG report disclosed:
| Governance Metric | 2023 Value |
|---|---|
| Independent Board Members | 10 out of 12 |
| Board Diversity | 42% women |
| Ethical Compliance Investigations | 12 total, resolved 100% |
Collaborative Innovation
Moderna maintained 27 strategic partnerships in 2023, including collaborations with:
- Merck & Co.
- AstraZeneca
- Vertex Pharmaceuticals
Global Health Commitment
COVID-19 vaccine distribution statistics:
| Global Distribution Metric | Cumulative Value |
|---|---|
| Total Vaccine Doses Shipped | 1.2 billion doses |
| Countries Supplied | 94 countries |
| Donation Programs | 37 million doses |
Moderna, Inc. (MRNA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.